These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31394834)

  • 1. Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production.
    Broos K; Lecocq Q; Keersmaecker B; Raes G; Corthals J; Lion E; Thielemans K; Devoogdt N; Keyaerts M; Breckpot K
    Vaccines (Basel); 2019 Aug; 7(3):. PubMed ID: 31394834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
    Broos K; Lecocq Q; Xavier C; Bridoux J; Nguyen TT; Corthals J; Schoonooghe S; Lion E; Raes G; Keyaerts M; Devoogdt N; Breckpot K
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.
    Awad RM; Lecocq Q; Zeven K; Ertveldt T; De Beck L; Ceuppens H; Broos K; De Vlaeminck Y; Goyvaerts C; Verdonck M; Raes G; Van Parys A; Cauwels A; Keyaerts M; Devoogdt N; Breckpot K
    Mol Ther Methods Clin Dev; 2021 Sep; 22():172-182. PubMed ID: 34485603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand
    Hu Z; Ma Y; Shang Z; Hu S; Liang K; Liang W; Xing X; Wang Y; Du X
    Oncol Lett; 2018 Apr; 15(4):5345-5351. PubMed ID: 29552177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.
    Pen JJ; Keersmaecker BD; Heirman C; Corthals J; Liechtenstein T; Escors D; Thielemans K; Breckpot K
    Gene Ther; 2014 Mar; 21(3):262-71. PubMed ID: 24401835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
    Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
    Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.
    Grenga I; Donahue RN; Lepone LM; Richards J; Schlom J
    Clin Transl Immunology; 2016 May; 5(5):e83. PubMed ID: 27350882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.
    Liu Q; Lv Y; Zhao M; Jin Y; Lu J
    Int J Clin Exp Pathol; 2015; 8(2):1374-83. PubMed ID: 25973021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
    Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
    Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained release of a human PD-L1 single-domain antibody using peptide-based hydrogels.
    Heremans J; Maximilian Awad R; Bridoux J; Ertveldt T; Caveliers V; Madder A; Hoogenboom R; Devoogdt N; Ballet S; Hernot S; Breckpot K; Martin C
    Eur J Pharm Biopharm; 2024 Mar; 196():114183. PubMed ID: 38246566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
    Gibbons Johnson RM; Dong H
    Front Immunol; 2017; 8():961. PubMed ID: 28848559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice.
    Wang J; Sun M; Zhu X; Zhao H; Mao D; Zhang Z; Zhao X
    Oncol Lett; 2019 Aug; 18(2):1539-1547. PubMed ID: 31423221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
    van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
    Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY; Park SH; Nam HJ; Choi DH; Sung YC
    J Immunother; 2011 Apr; 34(3):297-306. PubMed ID: 21389868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
    J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.